The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer

10.1001/jama.294.2.238

10.1097/00001622-200305000-00007

10.1016/S0094-0143(05)70163-4

10.1056/NEJMoa040720

10.1056/NEJMoa041318

10.1007/s00345-004-0473-1

CRAFT, 1999, Cancer Res., 59, 5030

10.1074/jbc.272.28.17485

10.1074/jbc.M108255200

10.1158/1078-0432.CCR-0974-3

10.1093/jnci/95.6.458

10.1038/6495

MIYAKE, 1999, Cancer Res, 59, 4030

MIYAKE, 2000, Cancer Res, 60, 170

MIYAKE, 2000, Cancer Res., 60, 3058

KIYAMA, 2003, Cancer Res., 63, 3575

10.1158/0008-5472.CAN-03-3998

McDONNELL, 1992, Cancer Res., 52, 6940

NICKERSON, 1999, Cancer Res., 59, 3392

10.1002/(SICI)1097-0215(20000615)86:6<855::AID-IJC15>3.0.CO;2-8

10.1002/pros.10047

MIYAKE, 2000, Endocrinology, 141, 2257, 10.1210/endo.141.6.7520

10.1158/1535-7163.MCT-05-0064

10.1016/1357-2725(95)00027-M

10.1016/S1357-2725(02)00041-9

10.1038/sj.onc.1204093

KHURI, 2000, Clin. Cancer Res., 6, 1607

10.1146/annurev.pharmtox.41.1.403

10.1517/13543784.8.3.237

10.1038/ki.1991.139

KYPRIANOU, 1991, Cancer Res., 51, 162

10.1210/endo-128-4-2091

10.1002/pros.2990080105

BRUCHOVSKY, 1990, Cancer Res., 50, 2275

KYPRIANOU, 1990, Cancer Res., 50, 3748

10.1006/excr.1996.0007

10.1093/jnci/91.20.1758

MIYAKE, 2000, Cancer Res., 60, 2547

MIYAKE, 2000, Clin. Cancer Res., 6, 1655

ZELLWEGER, 2002, Clin. Cancer Res., 8, 3276

10.1046/j.1464-410X.2003.04349.x

10.1002/pros.20087

10.1158/1535-7163.MCT-05-0064

MIYAKE, 2005, Oncol. Rep., 14, 1371

STEINBERG, 1997, Clin. Cancer Res., 3, 1707

10.1038/sj.pcan.4500722

10.1046/j.1523-1755.1998.00902.x

10.1172/JCI117043

10.1172/JCI116069

10.1038/ncb1291

10.4161/cbt.2.4.430

10.1074/jbc.M002055200

10.1074/jbc.C300252200

10.1074/jbc.274.11.6875

TAKAHASHI, 2004, Oncogene, 9, 9289, 10.1038/sj.onc.1208100

10.1042/bj3280045

10.1007/s00345-004-0474-0

10.1111/j.1442-2042.2005.01173.x

10.1158/0008-5472.CAN-04-2077

10.1038/sj.bjc.6602193

10.1158/0008-5472.CAN-04-0920

10.1074/jbc.M209233200

10.1038/sj.onc.1207404

10.1073/pnas.97.11.5907

10.1038/sj.cdd.4401254

10.1021/bi952981b

10.1002/pros.10158

SENSIBAR, 1995, Cancer Res., 55, 2431

MIYAKE, 2003, Oncol. Rep., 10, 469

10.1158/0008-5472.CAN-03-2664

10.4161/cbt.3.2.775

10.1016/S0002-9440(10)64552-X

HOUGH, 2001, Cancer Res., 61, 3869

MIYAKE H, GLEAVE M, KAMIDONO S, HARA I: Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence.Urology(2002) 59:150-154.

10.1016/S0022-5347(01)69130-4

10.1111/j.1464-410X.2005.05733.x

MIYAKE, 2001, Clin. Cancer Res., 7, 4245

10.1097/01.ju.0000118382.89456.f7

10.1593/neo.04478

10.1038/sj.neo.7900174

10.1073/pnas.84.22.7896

10.1073/pnas.90.18.8673

10.1016/0140-6736(90)90934-W

WESTERMANN, 1989, Biomed. Biochim. Acta, 48, 85

BAKER, 1992, J. Biol. Chem., 267, 11495, 10.1016/S0021-9258(19)49937-7

10.1146/annurev.pa.36.040196.000543

10.1007/BF02172105

10.1016/S0021-9673(01)87452-5

10.1038/nm0696-668

YAMANAKA, 2005, Oncol. Rep, 13, 885

10.1093/jnci/92.1.34

10.1002/1097-0215(200002)9999:9999<::AID-IJC1131>3.0.CO;2-Y

10.1002/(SICI)1097-4644(20000601)77:3<396::AID-JCB5>3.0.CO;2-5

GLEAVE, 1999, Clin. Cancer Res., 5, 2891

WAGNER RW: Gene inhibition using antisense oligodeoxynucleotides.Nature(1994) 372:333-335.

MONIA, 1993, J. Biol. Chem., 268, 14514, 10.1016/S0021-9258(19)85268-7

10.1093/nar/24.3.411

ZELLWEGER, 2001, J. Pharmacol. Exp. Ther., 298, 934

10.1038/nrc1631

10.1007/s00280-004-0997-5

10.1007/s10456-005-9018-5

10.1093/jnci/dji252

CHI, 2005, J. Clin. Oncol., 23, 213S, 10.1200/jco.2005.23.16_suppl.3085

10.2174/0929867054864859

10.2174/092986705774370664

ZANGEMEISTER-WITTKE, 2000, Clin. Cancer Res, 6, 2547

10.1093/jnci/93.6.463

JONES, 1995, Endocr. Rev., 16, 3

DEVERAUX QL, TAKAHASHI R, SALVESEN GS, REED JC: X-linked IAP is a direct inhibitor of cell-death proteases.Nature(1997) 388:300-304.

10.1002/(SICI)1097-0045(19970901)32:4<284::AID-PROS9>3.0.CO;2-J

YUEN, 1999, Clin. Cancer Res., 5, 3357

KONDO Y, KOGA S, KOMATA T, KONDO S: Treatment of prostate cancerin vitroandin vivowith 2-5A-anti-telomerase RNA component.Oncogene(2000) 19:2205-2211.

10.1517/13543784.11.12.1737